RIPE Knowledge Graph
RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1136%2Fbmj-2024-081557

https://w3id.org/ripe/ripe-kg/work/10.1136%2Fbmj-2024-081557
SubjectPredicateObject
ripekg:publication-details/RIPEA237F9DCBC31EFBBDFour cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial ripe:concerns ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
ripekg:registry-evidence/RIPEA237F9DCBC31EFBBD ripe:concerns ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
ripekg:research-integrity-assessment/RIPEA237F9DCBC31EFBBD ripe:assesses ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
ripekg:study-design-evidence/RIPEA237F9DCBC31EFBBD ripe:concerns ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial prism:doi 10.1136/bmj-2024-081557
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU068F2DADDC195A1BJing Yang
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU1408763677398895Hua-Long Kang
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU140ECFA76146BD31Ya-Jie Liu
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU1A3307C992305AF8Qiong Zhong
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU28C577200FA8143BChun-Yan Chen
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU3FA6B338DD3B6EC5Bi-Xiu Wen
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU4081D13EEEBD9AE6Yu-Jia Zhu
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU410921BFD9AE98FEYan Yuan
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU41C8F52E47EDC0E0Qiao-Xuan Wang
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU440E25D0FE4FD4EBWei-Hao Xie
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU49A4D95E77E85921Hui Chang
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU5796DFE6B48B1B32Jia-Wang Wei
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU67B56FE183D88DF9Li-Xia Lu
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU7CA3B177605D85A1Rong Huang
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAU9D96BCF112637B52Ming-Jun Xu
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUA4BE95C3CB80DAC4Xing-Yuan Shi
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUB15189653F9C9DCEHai-Hua Peng
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUB3AACADAD5FFB0D4Shi-Hai Wu
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUB5A85DC65A4E9B3BYong-Hong Hu
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUBA0A62799C615B7EXin-Hua Jiang
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUC0AD82537686CBBEWei-Wei Xiao
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUEC7D48CB43DDD7BFYuan-Hong Gao
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:creator ripekg:author/RIPEAUECD5CEC2E2E1904CTong-Chong Zhou
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial dcterms:title Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fcncr.10574Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fcncr.25754Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fcncr.30541Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fijc.32099Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fs00432-012-1219-xComparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.bioorg.2019.102925The first metal based anticancer drug
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.eclinm.2022.101625Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ejca.2019.07.007Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: longterm results of a phase III multicentre randomised controlled trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ijrobp.2009.09.040Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ijrobp.2010.03.024How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.oraloncology.2017.07.011Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.ygyno.2013.12.002Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs1470-2045%2816%2930410-7Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1023%2Fa%3A1008322415335Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG)
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1023%2Fa%3A1008360323986Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1038%2Fs41571-021-00524-xNasopharyngeal carcinoma: an evolving paradigm
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejmoa032260Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejmoa1905287Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fannonc%2Fmdy249Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1158%2F1055-9965.epi-06-0353The enigmatic epidemiology of nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.1995.13.10.2643
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2002.20.6.1593Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.2008.18.1545Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1200%2Fjco.22.00327Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: A multicenter, randomized phase III trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.1634%2Ftheoncologist.4-2-106Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.21147%2Fj.issn.1000-9604.2018.01.06Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1-4N2-3M0 nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.3322%2Fcaac.21834Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/10.7150%2Fjca.19197Evaluation of 7th edition of AJCC staging system for nasopharyngeal carcinoma
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/RIPEW15BD3071DDAD4FD2Micrometastasis: detection methods and clinical importance
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial http://purl.org/spar/cito/cites ripekg:work/RIPEW92CD9934BA894E47Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial rdf:type node1
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial rdf:type rdfs:Resource
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial rdf:type owl:Thing
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial rdf:type prov:Entity
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial rdf:type ripe:WorkWork
ripekg:work/10.1136%2Fbmj-2024-081557Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial owl:sameAs https://semopenalex.org/work/W4409447444